Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Lancet (London, England)
- Publicado em
- 25 nov 2022
- Citações
- 204
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
George R Thompson, Alex Soriano, Oliver A Cornely, Bart Jan Kullberg, Marin Kollef, Jose Vazquez, Patrick M Honoré, Matteo Bassetti, John Pullman, Methee Chayakulkeeree et al.
Descritores MeSH
- Candidiasis, Invasive
- Adult
- Candidiasis
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Treatment Outcome
- Echinocandins
Veja também
Estudos relacionados
- Efficacy and Safety of Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis in a China Cohort of a Double-Blind, Randomised, Phase 3 Trial (ReSTORE China)
- Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study
- Rezafungin vs caspofungin for the treatment of invasive candidiasis: A systematic review and meta-analysis
- Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses
- Análise bibliométrica e visual da pesquisa sobre o tratamento com equinocandina para infecções do trato urinário com base em VOSviewer e CiteSpace